Presentation is loading. Please wait.

Presentation is loading. Please wait.

Unbound drug concentrations in plasma (dotted) and brain ISF (solid, calculated from recovery and dialysate concentration) following repeated subcutaneous.

Published byVera Widjaja Modified over 5 years ago

Similar presentations

Presentation on theme: "Unbound drug concentrations in plasma (dotted) and brain ISF (solid, calculated from recovery and dialysate concentration) following repeated subcutaneous."— Presentation transcript:

1 Unbound drug concentrations in plasma (dotted) and brain ISF (solid, calculated from recovery and dialysate concentration) following repeated subcutaneous administration in rats, every 2 hours. Unbound drug concentrations in plasma (dotted) and brain ISF (solid, calculated from recovery and dialysate concentration) following repeated subcutaneous administration in rats, every 2 hours. Data are mean ± S.D., n = 3. For quinidine and desmethylclozapine, dialysate concentrations were measurable in only one of the three rats and therefore the S.D. values were not reported and brain:plasma ratios were not calculated. Matthew R. Durk et al. Drug Metab Dispos 2018;46: Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics

Download ppt "Unbound drug concentrations in plasma (dotted) and brain ISF (solid, calculated from recovery and dialysate concentration) following repeated subcutaneous."

Similar presentations

Martina Sahre1, Sreedharan Sabarinath1, PhD Maria Grant2, MD,

Martina Sahre1, Sreedharan Sabarinath1, PhD Maria Grant2, MD,
Do We Need to Optimize Protein Binding in Drug Discovery? NEDMDG Summary Meeting Xingrong Liu, Ph.D. Genentech.

Do We Need to Optimize Protein Binding in Drug Discovery? NEDMDG Summary Meeting Xingrong Liu, Ph.D. Genentech.
Representative 10-s EEG recordings from GAERS: during baseline (prior to injection of any drug) (i), following the i.c.v. injection of 4 μl of vehicle.

Representative 10-s EEG recordings from GAERS: during baseline (prior to injection of any drug) (i), following the i.c.v. injection of 4 μl of vehicle.
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.

Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.
Effects of cytokines on P450 mRNA expression in human hepatocytes.

Effects of cytokines on P450 mRNA expression in human hepatocytes.
Evaluation of models incorporating the base covariates.

Evaluation of models incorporating the base covariates.
The context-sensitive half-times for commonly used intravenous anesthetic drugs. [Reproduced from Reves JG, Glass PSA, Lubarsky DA, McEvoy MD, and Martinez-Ruiz.

The context-sensitive half-times for commonly used intravenous anesthetic drugs. [Reproduced from Reves JG, Glass PSA, Lubarsky DA, McEvoy MD, and Martinez-Ruiz.
Figure 3 Test reliability of enzymatic dissociation methods

Figure 3 Test reliability of enzymatic dissociation methods
Representative radio-HPLC chromatograms for individual pooled methanolic fecal extracts for periods of maximum recovery of radioactivity after dosing of.

Representative radio-HPLC chromatograms for individual pooled methanolic fecal extracts for periods of maximum recovery of radioactivity after dosing of.
HPLC tracings of resveratrol (RV) and its major sulfate conjugates M4/M5 in the plasma from three subjects. HPLC tracings of resveratrol (RV) and its major.

HPLC tracings of resveratrol (RV) and its major sulfate conjugates M4/M5 in the plasma from three subjects. HPLC tracings of resveratrol (RV) and its major.
Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.

Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.
Total ion current-EMS chromatograms of SB939 and its metabolites after incubation in liver microsomal fractions for 60 min at a concentration of 50 μM.

Total ion current-EMS chromatograms of SB939 and its metabolites after incubation in liver microsomal fractions for 60 min at a concentration of 50 μM.
Structure of solid lipid nanoparticles (SLNs).

Structure of solid lipid nanoparticles (SLNs).
The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action.

The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action.
Mechanisms of H2S release from S-aroylthiooximes (SATOs).

Mechanisms of H2S release from S-aroylthiooximes (SATOs).
Model B. The melatonin-produced increase in extracellular dopamine concentration in the striatum is prevented by the CYP2D inhibitor propafenone in pargyline-pretreated.

Model B. The melatonin-produced increase in extracellular dopamine concentration in the striatum is prevented by the CYP2D inhibitor propafenone in pargyline-pretreated.
Cytotoxic activities of polymer micelles containing CFZ in H460 (A) and select micelle formulations in RPMI-8226 (B) cell lines. Cytotoxic activities of.

Cytotoxic activities of polymer micelles containing CFZ in H460 (A) and select micelle formulations in RPMI-8226 (B) cell lines. Cytotoxic activities of.
Cytotoxic effects of PM1 and PM2 empty particle controls and coincubation of CFZ with empty particles tested in H460 (A) and RPMI-8226 (B) cells. Cytotoxic.

Cytotoxic effects of PM1 and PM2 empty particle controls and coincubation of CFZ with empty particles tested in H460 (A) and RPMI-8226 (B) cells. Cytotoxic.
Geometric mean concentration-time profiles of (A) racemic BUP, R-BUP, and S-BUP; (B) racemic OHBUP, RR-OHBUP, and SS-OHBUP; (C) racemic ERY, SR-ERYHBUP,

Geometric mean concentration-time profiles of (A) racemic BUP, R-BUP, and S-BUP; (B) racemic OHBUP, RR-OHBUP, and SS-OHBUP; (C) racemic ERY, SR-ERYHBUP,

Similar presentations

Ads by Google